Chordia Therapeutics Inc. [190A.T]
TOKYO, Apr 14 (Pulse News Wire) – Chordia Therapeutics (190A.T) reported a lower net profit of ¥21 million for the six months ended February 28, 2026, compared to a loss of ¥22 million in the same period last year. Operating expenses decreased by ¥37 million due to reduced research and development costs.
During the reporting period, the company made progress on its lead drug candidate rogocekib, advancing its clinical trials and securing additional funding through the issuance of subscription rights. Despite ongoing challenges in the pharmaceutical industry, Chordia continues to focus resources on developing innovative cancer treatments.
As of February 28, 2026, the company held cash reserves of ¥55 million, ensuring sufficient funds for operations over the next year. Additionally, Chordia successfully raised capital through the exercise of subscription rights, providing flexibility for future funding needs.
Chordia Therapeutics plans to continue prioritizing the development of rogocekib while exploring strategic partnerships for other pipeline projects to optimize resource allocation.
🟡 Confidence: Standard AI-translated content.